Welcome to our dedicated page for Mannkind SEC filings (Ticker: MNKD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MannKind Corporation filings document formal disclosures for a Nasdaq-listed biopharmaceutical company focused on inhaled and drug-device therapies. Its 8-K reports furnish operating results and business updates for Afrezza, Furoscix and pipeline programs, while also recording capital-structure events such as convertible-note settlement and material collaboration agreements involving the Technosphere platform.
The filing record also includes acquisition-related disclosures for the completed scPharma transaction, including acquired-business financial statements and pro forma combined financial information. MannKind proxy materials address annual meeting matters, executive compensation and equity-award information, and other governance subjects tied to its common stock.
MannKind Corporation, through a wholly owned merger subsidiary, will commence a tender offer to acquire all outstanding shares of scPharmaceuticals for $5.35 cash per share plus one non-tradeable contingent value right (CVR) that can pay up to an additional $1.00 per CVR based on two milestone tests. If the Offer is successful and conditions are met, Purchaser will merge into scPharmaceuticals, leaving scPharmaceuticals as a direct wholly owned subsidiary of MannKind.
The CVR pays up to $0.75, $0.50, or $0.25 per CVR for FDA approval timing of an injection product tied to SCP-111, and additional sales-based payments of up to $0.25 per CVR tied to $110.0–$120.0 million of trailing 12-month worldwide net sales. Principal stockholders holding approximately 11.5% of scPharmaceuticals have agreed to tender and support the transaction. Lenders led by Blackstone agreed to an amendment providing an additional $175.0 million incremental delayed-draw term loan to finance transaction costs, and Parent must repay and buy out Target’s Perceptive obligations estimated at $81.0 million on closing.
Dominic Marasco, President of the Endocrine Business Unit at Mannkind, received a significant performance-based equity award on June 23, 2025. The insider was granted 1,000,000 performance restricted stock units (PRSUs) that represent the right to receive an equivalent number of common stock shares.
Key terms of the PRSU grant:
- Vesting date set for March 15, 2028
- Final payout ranges from 0% to 200% of target shares based on net sales performance
- Target amount is 1,000,000 shares, meaning maximum potential payout is 2,000,000 shares
- Exercise price of $0, making this a full-value award
This significant equity grant aligns the executive's interests with long-term company performance, specifically tied to net sales targets over an approximately 3-year performance period.